TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom -15.9% · netto nieuwe posities -4.3% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 151 | +7 | 369.28M | $12.48B | +9 | −1 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | n/a | n/a |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | n/a | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | n/a | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | n/a |
| Q2 2024 | 19 | n/a | 61.88M | $1.01B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 57.80M | +6.4% | $1.17B | 0.0% | ▲ Add | 2 | SEC ↗ ×20 |
| 2 | Fidelity (FMR) ✦ | 24.64M | -57.6% | $497.76M | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 3 | State Street Global Advisors ✦ (passief) | 17.15M | -0.8% | $346.44M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Glenview Capital ✦ | 16.69M | +5.5% | $337.19M | 8.2% | ▲ Add | 6 | SEC ↗ |
| 5 | Duquesne Family Office ✦ | 16.59M | +3.9% | $335.20M | 8.5% | ▲ Add | 5 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passief) | 9.99M | +3.7% | $200.48M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Wellington Management ✦ | 6.90M | +39228.4% | $139.30M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 8 | Morgan Stanley ✦ | 6.48M | n/a | $130.80M | 0.0% | n/c | 1 | SEC ↗ ×13 |
| 9 | Goldman Sachs Group ✦ | 5.09M | n/a | $102.73M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Greenlight Capital (DME Capital) ✦ | 3.78M | 0.0% | $76.33M | 3.0% | Held | 6 | SEC ↗ ×2 |
| 11 | JPMorgan Chase ✦ | 2.77M | n/a | $55.96M | 0.0% | n/c | 1 | SEC ↗ ×24 |
| 12 | Viking Global Investors ✦ | 2.53M | -78.3% | $51.15M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 1.23M | -44.2% | $24.93M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Millennium Management ✦ | 1.07M | -2.8% | $21.57M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 1.00M | -68.2% | $20.25M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | The Vanguard Group ✦ (passief) | 900.99K | +1.8% | $18.20M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 17 | Bridgewater Associates ✦ | 864.78K | Nieuw | $17.47M | 0.1% | New | 1 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 508.70K | +10.3% | $10.28M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 19 | D. E. Shaw & Co. ✦ | 169.17K | +38.9% | $3.42M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 120.40K | -62.4% | $2.43M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | ARK Investment Management ✦ | 118.72K | -1.8% | $2.40M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | GAMCO Investors ✦ | 89.20K | 0.0% | $1.80M | 0.0% | Held | 6 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 44.20K | +69.8% | $892,738 | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $17.47M | 0.1% |
Verlaten
| Norges Bank | $31.25M | was 0.0% |
| Adage Capital Partners | $8.95M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 646 houders, 666.61M aandelen, $16.70B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 2.52K aand · $98,841
Director · 367.60K aand · $14.36M
Officer · 4.50K aand · $174,221
Officer · 314 aand · $12,153
Officer · 2.50K aand · $94,077
Director · 415 aand · $15,459
Officer · 6.95K aand · $261,224
Officer · 18.60K aand · $680,291
Director · 17 aand · $593
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie